CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Site Search
Showing 1 - 5 of 5 results
Press Release
|
|
3 min read
Press Release
|
|
4 min read
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Press Release
|
|
2 min read
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
Press Release
|
|
3 min read
Managing cystic fibrosis can feel overwhelming at times — but we’re here to help. Learn how to navigate life with CF.